Olga Vasiljeva

Olga Vasiljeva has a diverse work experience spanning multiple companies. Olga began their career in 1999 as a Principal Investigator at Jozef Stefan Institute, where they worked until 2011. In 2004, they also held a position as a Postdoctoral Scientist at the University of Freiburg for two years.

Since 2011, Olga has been at CytomX Therapeutics, taking on various roles. Olga started as the Principal Scientist and Head of Protease Biology, a position they held until 2015. From 2015 until 2023, they served as an Executive, Senior, and later, Director of Platform Biology. Since 2023, Olga has been working as the Vice President of Platform Biology and Bioanalysis at the company.

Overall, Olga Vasiljeva has demonstrated expertise in biology and bioanalysis throughout their career, with a focus on protease biology and platform biology.

Olga Vasiljeva pursued their education in the field of medical sciences. From 1999 to 2003, they attended Jozef Stefan Institute / Siberian State Medical University, where they obtained a Ph.D. in Medical Sciences. During this time, their studies focused on physiology, biochemistry, and protease biology. Following their doctoral studies, they then undertook a postdoctoral fellowship in molecular medicine from 2004 to 2006 at the Institute of Molecular Medicine and Cell Research, Albert-Ludwigs-University. Olga'sresearch during this period centered on molecular oncology and protease biology.